GlassScriptPhysician profile
Herbert A Fischer
NPI 1902988397
$10,375.90
in general payments reported to CMS, 2019-2025
45 companies · $1,700 in 2025
The $1,700 reported for 2025 was more than what 81% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,779 · 2020: $582 · 2021: $1,450 · 2022: $576 · 2023: $2,084 · 2024: $2,204 · 2025: $1,700.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,978 · Education: $10.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,977.70 |
| Education | $10.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,683.68 | 2019-2025 | Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $1,366.58 | 2019-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $1,152.87 | 2019-2025 | |
| Pfizer INC. | $1,101.77 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $765.16 | 2019-2025 | Farxiga, Wainua, Lokelma |
| Merck Sharp & Dohme LLC | $500.01 | 2019-2025 | Verquvo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $426.09 | 2020-2025 | Jardiance |
| Esperion Therapeutics, INC. | $418.68 | 2021-2025 | Nexletol |
| E.R. Squibb & Sons, L.L.C. | $384.49 | 2019-2025 | Eliquis, Camzyos |
| Amarin Pharma, INC. | $367.57 | 2019-2022 | |
| Novo Nordisk INC | $260.63 | 2019-2024 | Ozempic, Wegovy |
| Lexicon Pharmaceuticals, INC. | $215.02 | 2023-2024 | Inpefa |
| Edwards Lifesciences Corporation | $170.47 | 2019-2024 | Edwards Sapien 3 Ultra Transcatheter Heart Valve, Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Sanofi-Aventis U.S. LLC | $165.01 | 2019-2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $148.94 | 2023 | Lifevest |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Herbert Fischer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.